Overview of Dvella

Property	Description
Active ingredient	Ulipristal Acetate (UPA)
Form	Tablet for oral use
Pharmacological class	Selective Progesterone Receptor Modulator (SPRM)
Common use	Emergency contraception (non-routine backup method)
Origin	Synthetic 19-norprogesterone derivative

The Pharmaceutical Identity of Dvella

Dvella is a synthetic, single-ingredient, prescription-only pharmaceutical preparation whose active compound is Ulipristal Acetate (UPA). This substance is chemically recognized as a derivative of 19-norprogesterone, confirming its synthetic origin as a hormonal agent. Pharmacologically, it belongs to the advanced class of medications designated as Selective Progesterone Receptor Modulators (SPRMs).

As an SPRM, Ulipristal Acetate differentiates itself from older, non-selective hormonal options because it actively modulates—rather than simply mimicking or blocking—the progesterone receptor. This mechanism is clinically recognized for providing a distinct mechanism compared to progestin-only alternatives. The preparation is specifically positioned as a post-coital option for adult women of reproductive age, distinguishing its target user group. This medicine is distinct from routine, daily contraceptive methods and is designed exclusively for occasional, time-critical application.

Composition, Form, and General Purpose

Dvella is supplied as an oral tablet, which is the dosage form optimized for rapid systemic absorption following oral administration. The composition is intentionally focused, consisting solely of the active ingredient, Ulipristal Acetate, combined with necessary solid pharmaceutical excipients to create the finalized tablet.

The general purpose of this medicine is to provide a non-routine backup method to help prevent pregnancy when utilized after unprotected sexual intercourse or documented contraceptive failure. This function is achieved through its fundamental antiprogestational activity, meaning it interferes with the normal hormonal sequence of the reproductive cycle by inhibiting or delaying ovulation. This indicates that the medication's primary job is to interrupt the key stages that lead to conception. The preparation is intended only for occasional use in these specific, unplanned circumstances, consistent with its classification as an emergency intervention.

Regulatory References

What side effects are possible with Dvella?

Possible Side Effects and Safety Information

Official regulatory documents classify adverse reactions to Ulipristal Acetate based on their expected frequency and the affected body system. Most documented effects are acute, generally mild to moderate, and typically resolve within a short timeframe following administration.

Frequency-Classified Adverse Reactions

The most frequently documented side effects are classified as Very Common (ge 1/10), primarily including headache, nausea, abdominal pain, and painful menstruation (dysmenorrhea). Effects classified as Common (ge 1/100 to < 1/10) include fatigue, dizziness, vomiting, breast tenderness, back pain, pelvic pain, and mood disorders.

Adverse reactions are grouped into System-Organ Classes, with the Nervous System (headache, dizziness), Gastrointestinal System (nausea, abdominal pain), and Reproductive System (dysmenorrhea, breast tenderness) being the most commonly affected areas reported in clinical data.

Serious Safety Considerations and Limitations

Specific safety warnings in official labeling require that the possibility of an Ectopic Pregnancy must be excluded in women who become pregnant or present with lower abdominal pain following treatment. Due to the lack of dedicated studies, use is generally not recommended in patients with severe hepatic impairment.

Regulatory safety constraints emphasize that this medicine is strictly intended for occasional emergency use and is not to be used as a replacement for routine contraceptive methods. Furthermore, the official prescribing information notes that changes to the subsequent menstrual period, such as an earlier or later arrival, are a recognized effect shortly after administration.

Overdose and Emergency Response

Overdose and when to seek help

Documented Overdose Profile

Clinical experience involving single doses of Ulipristal Acetate up to 200 mg (over six times the normal dose) indicates that overdose effects are typically mild and non-serious. The documented manifestations observed in these high-dose exposures affect the gastrointestinal system, presenting as nausea and vomiting. Effects on the reproductive system include a shortened menstrual cycle, with bleeding occurring 2–3 days earlier than expected, and a prolonged duration of bleeding, which is usually mild or spotting. Regulatory records confirm that no serious or life-threatening adverse reactions have been observed following the high-dose exposures studied.

Emergency Actions and Management

In the event of a suspected overdose, it is officially mandated to seek immediate medical attention. Management of the overdose is directed toward symptomatic and supportive care, as official regulatory documentation confirms that no specific antidote is known. A critical exposure-related factor requires a specific action: if the patient vomits within three hours of administration, official guidance states that a repeat dose should be considered to ensure the medication’s efficacy. This action is distinct from managing toxicity but is a required emergency step tied to absorption failure.

Therapeutic Uses of Dvella

What Dvella Treats: Main Uses and Benefits

Dvella (Ulipristal Acetate) is specifically used for emergency contraception following unprotected sexual intercourse or documented contraceptive failure. The core therapeutic domain of the active ingredient involves acute risk management in reproductive health, and is not used for managing existing symptoms or chronic conditions.

This medicine is generally applied in clinical settings that involve an acute, non-routine risk of conception, addressing conditions associated with acute or disruptive episodes, such as following a lapse in or failure of routine contraception. The primary benefit provided is a reduced likelihood of pregnancy, which supports the patient during difficult episodes by easing distress.

H3 — Backup Support for Contraceptive Failure

The preparation is commonly used across conditions presenting with sudden episodes of exposure where supportive symptom management is appropriate. It is relevant for managing symptoms that interfere with daily comfort and may be part of symptomatic management used to address the risk of unintended pregnancy.

Quick Fact: Relief for Acute Risk Dvella provides supportive relief that contributes to easing the overall symptom load following a contraceptive failure, and assists with maintaining functional stability during this time-sensitive scenario.

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Dvella — Official Regulatory Information

The eligibility profile for Dvella (Ulipristal Acetate) is strictly defined by regulatory documents, outlining populations permitted, restricted, or prohibited from using the medicine.

Eligibility Scope

Category	Official Regulatory Statement
Populations for whom use is allowed	Women of childbearing potential, including adolescents who have reached menarche (started menstruating).
Populations for whom use is not recommended	Patients with severe hepatic (liver) impairment due to lack of specific studies in this restricted population.
Populations for whom use is contraindicated	Women with a known or suspected existing pregnancy, or known hypersensitivity to ulipristal acetate.

Condition-Specific Eligibility Rules

Use is contraindicated in cases of severe asthma that is insufficiently controlled by oral glucocorticoids.
It is also contraindicated in patients with undiagnosed abnormal uterine bleeding.
Caution is advised when considering use in patients with severe renal (kidney) impairment.

Pregnancy and Lactation Eligibility Status

Pregnancy: The medicine is contraindicated if pregnancy is suspected or confirmed.
Lactation: Regulatory guidance recommends that nursing should be suspended for one week (seven days) following administration.

Eligibility-Related Restrictions

Age-Related: The medicine is not intended for use in pre-pubertal or post-menopausal women.
Repeat Use: Repeated use within the same menstrual cycle is not recommended, as the safety and efficacy for such use have not been established.

Connection to the Overall Eligibility Profile

Official documents define eligibility by establishing absolute prohibitions on use for specific health and pregnancy statuses and by restricting use in populations where clinical data is insufficient. These rules strictly outline the boundaries of authorized use for this single-dose medicine.

What should I know about interactions with other medicines?

Dvella Interactions with other medicines and products

Dvella (Ulipristal Acetate) possesses a defined interaction profile that governs its use with specific medicinal products and substances. The most crucial restriction involves a contraindication for co-administration with strong CYP3A4 inducers. This category includes drugs such as Rifampin, Phenytoin, and certain Barbiturates. Co-use with these agents is prohibited because they significantly decrease the plasma concentration of Ulipristal Acetate, which may compromise its intended action. Conversely, strong CYP3A4 inhibitors, such as Ketoconazole, are known to increase the exposure of Ulipristal Acetate.

A second, clinically significant interaction occurs with progestin-containing hormonal methods. This is a pharmacodynamic antagonism where the hormonal method may impair Dvella’s ability to delay ovulation. Consequently, a mandatory, timing-based interaction rule applies: hormonal contraception must not be initiated or resumed sooner than 5 days following the intake of Dvella.

The official interaction documentation extends to the herbal product St. John’s Wort, which is classified as a CYP3A4 inducer and may decrease effectiveness. The medication can be taken with or without food as the resulting delayed absorption does not affect clinical outcome. The official labeling contains no documented notes regarding altered interaction severity in patient populations with hepatic or renal impairment.

Mechanism of Action

Selective Modulation of Progesterone Signaling

Dvella's active ingredient, Ulipristal Acetate (UPA), is a Selective Progesterone Receptor Modulator (SPRM) that acts as a high-affinity ligand for the intracellular nuclear Progesterone Receptor (PR). UPA exhibits a competitive antagonistic effect, inhibiting the binding and signaling of endogenous progesterone within reproductive tissues. This targeted molecular interaction is central to disrupting the cascade that governs the menstrual cycle.

⏱️ Inhibiting the Pre-Ovulatory Cascade

The central physiological effect is the suppression of the Luteinizing Hormone (LH) surge, which is the acute hormonal trigger from the Hypothalamic-Pituitary-Ovarian (HPO) Axis required for final follicular rupture. This interference causes the inhibition or significant delay of ovulation, resulting in a temporal mismatch with the viable lifespan of sperm within the female reproductive tract. This mechanism is fundamentally constrained to the pre-ovulatory phase; its action does not extend to the state of established implantation.

Dosage and Administration Information

How to Use Dvella: Official Administration Guidelines

Dvella (Ulipristal Acetate) is a single-dose oral prescription medicine intended for use as an emergency contraceptive. The usage protocol includes specific time constraints and administration procedures.

Administration Scope

Parameter	Official Instruction
Route of administration	The medicine is administered orally (by mouth).
Dosing schedule	A single, fixed dose of 30 mg (one tablet) is to be taken per acute event.
Timing in relation to meals	May be taken with or without food.
Age-group administration rules	The medicine is suitable for women of child-bearing age, including adolescents who have reached menarche.
Special procedural conditions	The tablet must be taken as soon as possible, but no later than 120 hours (5 days), following unprotected sexual intercourse or documented contraceptive failure.

Resulting Procedural Structure

Official step sequence:

The time of administration must be confirmed to be within the 120-hour window following the event.
The single 30 mg tablet is administered orally, independent of food intake or the current phase of the menstrual cycle.
A key administration rule specifies that if vomiting occurs within 3 hours of taking the tablet, a complete second dose of 30 mg must be taken immediately.

Connection to the Overall Use Protocol

This framework mandates the use of Dvella as a time-sensitive, one-time intervention based on a fixed oral dose. The usage is strictly defined by the need for administration within the 120-hour window and includes a specific procedural step to address insufficient initial dosing due to vomiting. These parameters ensure the standardized application of the medicine.

Recent Clinical Evidence

Research evidence / Overview of studies for Dvella

Evidence for Use in Emergency Contraception

Research examining Dvella (Ulipristal Acetate) has primarily focused on its use in research exploring conditions associated with acute or disruptive episodes following a single episode of unprotected sexual intercourse or when routine contraception has failed. The evidence base for this use relies mainly on large, well-controlled, short-term randomized controlled trials (RCTs) that formed the basis of the regulatory filing by bodies such as the FDA and the EMA. These trials research examined the observed rate of pregnancy in women who received the treatment, comparing that rate to the calculated expected rate of pregnancy in the study protocols. Subsequent systematic reviews and meta-analyses have pooled these findings, contributing to the broader evidence landscape.

Studies on the Time Window and Mechanism

Beyond the main clinical trials, smaller, more controlled studies known as pharmacodynamic (PD) studies were conducted to explore how the medicine was studied for outcomes related to systemic or functional imbalance. These studies did not look at the final clinical outcome but instead monitored temporary physiological imbalance by measuring hormonal changes and using ultrasound to look at follicular size. This research examined whether the medicine was associated with outcomes related to the monitoring of key physiological changes.

Research has also explored outcomes related to the medicine across the time frame of up to 120 hours, as defined in the study protocols. While studies observed responses over defined time intervals, data show patterns related to higher statistical precision in the data collected within the first 72 hours after intercourse. The research provides context but not individual predictions, and data show patterns related to this time-sensitive scenario.

What Is Still Uncertain About Dvella’s Research

Despite the high quality of the initial RCTs, subgroup findings are uncertain in several areas. For instance, comparative evidence is lacking with other non-hormonal emergency contraceptive options. As noted, evidence quality varies across studies when it comes to the full 120-hour window, as sample sizes were modest in the later hours of treatment. Data for certain groups remain insufficient, particularly for patients with specific health conditions that were not a focus of the primary clinical trials.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Dvella (FAQ)

Q: Is Dvella the same type of medicine as other treatments for this condition?

Dvella is described in official regulatory documents as a Selective Progesterone Receptor Modulator (SPRM). This classification reflects a targeted approach, meaning it acts differently at the progesterone receptor compared to older hormonal emergency contraceptive options.

Q: Why is Dvella prescribed instead of another similar drug?

Official information indicates that Dvella is intended for use up to 120 hours (5 days) following unprotected intercourse. This time window is a key distinction from some other emergency contraceptive options.

Q: Can Dvella be used by people with kidney or liver problems?

Official documents state that Dvella is not recommended for patients with severe hepatic (liver) impairment due to a lack of dedicated studies in this group. For renal (kidney) impairment, no specific dose adjustment is generally noted for mild or moderate cases, but regulatory guidance indicates that severe cases may require close monitoring.

Q: What is the difference between Dvella and a supplement for this condition?

Dvella is a prescription-only pharmaceutical medicine containing a defined active ingredient (Ulipristal Acetate) that has been reviewed and approved by government health authorities. Supplements are generally regulated under a different set of rules compared to prescription drugs.

Q: Are the side effects of Dvella generally mild or severe?

The adverse effects documented in clinical data are generally classified as mild to moderate in severity. They are typically acute, meaning they resolve shortly after administration.

Q: What happens if I miss a dose of Dvella?

Dvella is a single-dose medicine intended for a one-time acute event, so the idea of 'missing a dose' is not applicable. However, administration guidelines describe a procedure where, if vomiting occurs within 3 hours of taking the tablet, a complete second dose is taken immediately.

Q: What should I do if I accidentally take two doses of Dvella?

Regulatory safety information indicates that experience with accidental overdose is limited. Clinical data from subjects who received single doses significantly higher than the standard dose reported no severe or serious adverse reactions.

Q: Is Dvella effective in all patients who take it?

As with any medication, official studies indicate that it is not associated with preventing pregnancy in all patients. Clinical trials reported an observed pregnancy rate compared to an expected rate, which formed the basis for its regulatory approval.

Q: How long do the effects of Dvella typically last?

The medicine’s active compound is described as having a terminal half-life of approximately 30 hours. The functional effect of delaying ovulation is described in studies as lasting for at least 5 days when taken before the key hormonal trigger.

Q: Where can I find the official patient information leaflet for Dvella?

Official patient information, such as the Patient Information Leaflet (PIL) or Patient Package Insert (PPI), is generally provided by the dispensing pharmacist. These documents are also available on official government drug databases like DailyMed or the EMA website.

Q: How quickly should I expect Dvella to start working?

The medicine is generally rapidly absorbed after being taken orally. While food intake may delay the time it takes to reach peak concentration in the body, regulatory documents state that this change in absorption does not affect the intended clinical outcome.

Q: Do I need to change my diet while taking Dvella?

The official label contains no documented notes regarding the need for patients to change their diet while using the medicine. It can be taken with or without food.

Q: Are there any common foods or drinks that interact with Dvella?

Regulatory information indicates that no known interactions have been documented between Dvella and common foods or drinks.

Q: How is Dvella removed from the body?

The primary route of excretion for the active compound and its metabolites is through the faeces (liver/biliary excretion), with a smaller amount removed via the urine (renal excretion).

Q: Is there a specific time of day that is best for taking Dvella?

Regulatory guidance emphasizes that the medicine should be taken as soon as possible within the 120 hour window after the event. There is no specific instruction in the official documentation for an optimal time of day.

Q: What is the maximum duration Dvella has been studied for use?

Dvella is indicated strictly as a single-dose, occasional emergency intervention. Regulatory documents explicitly state the medicine is not for routine use or for repeated use within the same menstrual cycle.

Q: Is a tapering schedule needed when stopping Dvella?

Because Dvella is a single-dose medicine intended for a one-time acute event, a tapering schedule is not applicable to its use.

Q: Is it possible to develop an allergy to Dvella?

Known or suspected hypersensitivity to the active ingredient is listed as a contraindication in official documents. Hypersensitivity covers the potential for a severe allergic reaction.

Q: Can Dvella cause problems with sleep?

The safety information notes that Somnolence (drowsiness) is classified as an uncommon side effect. Disturbances in attention have been rarely reported.

Q: Are there specific symptoms that signal an emergency while on Dvella?

Official labeling notes that the possibility of an ectopic pregnancy is a critical safety consideration. If a woman becomes pregnant or presents with lower abdominal pain after taking the medicine, regulatory warnings describe the necessity of excluding this condition.

Q: How does alcohol consumption affect Dvella?

The official regulatory information does not contain documented notes regarding the effect of alcohol consumption on Dvella. There is no specific warning or instruction related to consuming alcohol with this medicine.

Q: What are the results of the key phase 3 trials for Dvella?

Clinical trials examined the observed rate of pregnancy compared to the calculated expected rate. Studies showed the medicine prevented approximately 62 to 85% of expected pregnancies in the study population.

How should Dvella be stored and disposed of?

How to Store and Dispose of Dvella (Ulipristal Acetate)

Official regulatory documents define specific conditions for storing and handling Dvella tablets to preserve the product's quality and stability.

Storage Requirements

Dvella must be stored at room temperature and is required to be kept in a closed container.

Storage Restriction	Requirement
Temperature	Keep from freezing and away from heat
Protection	Protect from moisture and direct light
Packaging	Keep the blister in the outer carton
Safety	Must be stored out of the reach of children

Disposal Instructions

The official label instructs that patients ask a healthcare professional how to dispose of any unused or outdated medicine. Disposal must be carried out in accordance with local regulatory requirements for pharmaceutical products.

Dvella